Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 7/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | CKS1B | P61024 | 2/20 | 0.38 |
| ▸ | SKP1 | P63208 | 2/20 | 0.38 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.38 |
| ▸ | HPGDS | O60760 | 2/20 | 0.37 |
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
| ▸ | ABHD6 | Q9BV23 | 2/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.36 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.36 |
| ▸ | KIT | P10721 | 1/20 | 0.35 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4988573 | 0.89 | CYP11B2 (0.36) | — | |
| SCHEMBL13341052 | 0.86 | EGFR (0.39) | USP30EGFRSRCCKS1BSKP1 | |
| SCHEMBL13341055 | 0.84 | EGFR (0.38) | USP30EGFRSRCCKS1BSKP1 | |
| SCHEMBL8238138 | 0.84 | USP30 (0.38) | USP30EGFRSRCCKS1BSKP1 | |
| SCHEMBL8238426 | 0.79 | ABHD6 (0.47) | USP30EGFRSRCHPGDSABHD6 | |
| SCHEMBL13341217 | 0.79 | SRC (0.34) | USP30EGFRSRCCKS1BSKP1 | |
| SCHEMBL13705167 | 0.78 | ABHD6 (0.47) | USP30EGFRSRCHPGDSABHD6 | |
| SCHEMBL3494480 | 0.77 | CYP11B2 (0.35) | — | |
| SCHEMBL8238579 | 0.76 | ABHD6 (0.46) | USP30EGFRSRCHPGDSABHD6 | |
| SCHEMBL8235939 | 0.76 | ABHD6 (0.46) | USP30EGFRSRCABHD6DAGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100121048-A1 | Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100121048-A1 | Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension | REN, AGTR1, AGTR2 | USP30 2733/4885EGFR 1629/4885SRC 967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.